Mantle Cell Lymphoma

Loretta J. Nastoupil, MD, discusses ongoing lymphoma clinical trials and how practitioners can better identify high- and poor-risk patients with large cell lymphomas.

Two oncologists from Emory University School of Medicine faced off to determine if molecular markers should play a role in the treatment of subgroups of patients with diffuse large B-cell lymphoma. 

According to findings from a multicenter randomized trial, chemoradiation for early-stage, low-grade follicular lymphoma led to significant improvement in progression-free survival (PFS) compared with involved-field radiotherapy alone (IFRT).

Pembrolizumab (Keytruda) is associated with an exceptional overall response rate (ORR) in patients with relapsed/refractory Hodgkin lymphoma.

A majority of patients (66%) with classical Hodgkin lymphoma (cHL) who had progressed after receiving autologous stem cell transplant (ASCT) and brentuximab vedotin (adcetris) experienced a response to nivolumab (Opdivo) monotherapy, findings from the phase II CheckMate-205 trial showed when presented at the 2016 ASCO Annual Meeting.

Michael E. Williams, MD, discusses emerging regimens on the horizon in mantle cell lymphoma, the potential of BCL-2 inhibition, and whether chemotherapy can be removed entirely from the treatment landscape.

The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda) as a treatment for patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

The FDA has granted nivolumab (Opdivo) a priority review for use in previously treated patients with classical Hodgkin lymphoma (cHL), giving the drug the potential to become the first PD-1 inhibitor approved for a hematologic malignancy.

John Leonard, MD, discusses the number of options doctors have to choose from when treating follicular lymphomas.

Expanding on the efficacy shown in numerous single-group studies, a phase II study published in The Lancet Oncology showed lenalidomide significantly increased progression free survivalin patients with relapsed or refractory mantle cell lymphoma.

Six ongoing clinical trials investigating several idelalisib (Zydelig) combinations have been halted due to reports of increased adverse events such as death for patients with hematologic malignancies, according to an alert issued by the FDA.

Obinutuzumab (Gazyva) plus bendamustine, followed by obinutuzumab alone has been approved by the FDA as a treatment of patients with follicular lymphoma who were not responsive to a rituximab regimen, or who relapsed after rituximab-based therapy.

In this article, Shipra Gandhi, MD, Pallawi Torka, MD, and Francisco J. Hernandez Ilizaliturri, MD summarize the current clinical development of these novel agents in lymphoid malignancies.

Peter Martin, MD, discusses the evolving paradigm of treatment for mantle cell lymphoma. Martin says the evolution of the paradigm currently includes Bruton's tyrosine kinase inhibitor, phosphoinositide 3-kinase inhibitor, immunomodulatory treatments, and immunotherapies.

​John McCarty, MD, medical director, Bone Marrow Transplant Program, Virginia Commonwealth University Health, discusses advice physicians can give to patients with lymphoma seeking stem cell mobilization.

Patrick Johnston, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses a phase I study that incorporated belinostat with standard CHOP chemotherapy for patients with newly diagnosed peripheral T-cell lymphoma. Johnston says the goal of the trial was to discover the maximum tolerable dose. He said there were no additional significant toxicities in patients and the combination was well-tolerated.

In this review, our authors discuss the mechanism of action and clinical development of various checkpoint inhibitors in lymphoma.

Ibrutinib (Imbruvica) saw over 80% response in patients with treatment-refractory Waldenstrom

Two CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies showed complete response (CR) rates from 90% to 100% in patients with high-risk acute lymphoblastic leukemia (ALL), according to data from two studies presented during the 2015 ASH Annual Meeting.

Updated data shows chimeric antigen receptor (CAR)-modified T-cell therapies continue to remain effective for patients with non-Hodgkin lymphoma (NHL), according to findings presented at the 2015 ASH Annual Meeting.

Ibrutinib reduced risk of death by 84% against chlorambucil in treatment-naive elderly patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma.

When John P. Leonard, MD, spoke at the American Society of Hematology inaugural meeting on Hematologic Malignancies about mantle cell lymphoma (MCL), he balanced his enthusiasm about the emerging benefits that tumor profiling brings to this disease with an acknowledgement that many important questions about mantle cell lymphoma remain unanswered.

New combination strategies are required for heterogeneity of mantle cell lymphoma (MCL), in order to improve outcomes.

The development of novel targeted drugs, such as brentuximab vedotin (Adcentris), against discrete cell surface proteins, such as CD30, has awakened a new way of thinking about targeted cancer biology

Infusions of CTL019, a CAR-modified T-cell therapy against CD19, achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive DLBCL, MCL, and FL.